Heron's non-opioid HTX-011 gets Priority Review

Heron's non-opioid HTX-011 gets Priority Review

Submitted by admin on January 2, 2019 - 6:49pm
Source: 
BioCentury
News Tags: 
priority review
Heron Therapeutics
HTX-011
post-operative pain
Headline: 
Heron's non-opioid HTX-011 gets Priority Review
snippet: 

FDA accepted and granted Priority Review to an NDA for HTX-011 from Heron Therapeutics Inc. (NASDAQ:HRTX) for postoperative pain management. The PDUFA date is April 30.

Do Not Allow Advertisers to Use My Personal information